Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
enrollment
Biotech
Regeneron seeks clarity on confirmatory trials after FDA hurdle
Regeneron's Andres Sirulnik says blood cancer medicine odronextamab enrollment is going fine, days after FDA rejection.
Annalee Armstrong
Mar 29, 2024 5:00am
Mirum blames enrollment woes for halting phase 2 trial
Nov 29, 2022 9:50am
Kronos blames enrollment troubles for ending phase 3 AML program
Nov 9, 2022 8:19am
Salarius pauses enrollment of sarcoma trial after patient death
Oct 18, 2022 9:50am
People more likely to take part in decentralized trials: study
Jul 15, 2022 10:05am
Nordic Nanovector pulls the plug on troubled Paradigme trial
Jul 6, 2022 11:26am